APA (7th ed.) Citation

N, M., J, S., J, F., A, C., H, R., K, E., . . . RB, W. (2026). Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. Dermatology and therapy, 16(7), 3415. https://doi.org/10.1007/s13555-026-01779-x

Chicago Style (17th ed.) Citation

N, Magnolo, et al. "Risankizumab Versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial." Dermatology and Therapy 16, no. 7 (2026): 3415. https://doi.org/10.1007/s13555-026-01779-x.

MLA (9th ed.) Citation

N, Magnolo, et al. "Risankizumab Versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial." Dermatology and Therapy, vol. 16, no. 7, 2026, p. 3415, https://doi.org/10.1007/s13555-026-01779-x.